Cover Image
市場調查報告書

多形性膠質母細胞瘤(GBM):開發中產品分析

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 229730
出版日期 內容資訊 英文 1759 Pages
訂單完成後即時交付
價格
Back to Top
多形性膠質母細胞瘤(GBM):開發中產品分析 Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018
出版日期: 2018年06月22日 內容資訊: 英文 1759 Pages
簡介

多形性膠質母細胞瘤(GBM),是最常見的惡性原發性腦瘤。GBM是由星狀神經膠細胞(形成保護大腦及脊髓內神經細胞的細胞)開始產生的。GBM由星形膠質細胞所構成。症狀有緩慢惡化的神經病變,通常是由於運動麻痺、頭痛、顱內增壓造成的全身症狀(頭痛、噁心、嘔吐、認知障礙、中風等)。治療方法包含放射線治療,化療等。

本報告提供多形性膠質母細胞瘤(GBM)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

多形性膠質母細胞瘤(GBM)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10532IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 108, 67, 1, 9, 160, 28 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 15, 1, 43 and 10 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Glioblastoma Multiforme (GBM) - Overview
  • Glioblastoma Multiforme (GBM) - Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics Assessment
  • Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Drug Profiles
  • Glioblastoma Multiforme (GBM) - Dormant Projects
  • Glioblastoma Multiforme (GBM) - Discontinued Products
  • Glioblastoma Multiforme (GBM) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..14), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..11), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..12), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..13), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..14), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..15), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..16), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..17), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..18), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..19), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..20), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..21), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018
  • Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018
  • Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018
  • Number of Products by Stage and Target, H1 2018 (Contd..9), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..9), H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2018
  • Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2018

List of Figures

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top